KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bausch Health Companies (BHC) EBITDA Margin (2016 - 2025)

Bausch Health Companies (BHC) has disclosed EBITDA Margin for 17 consecutive years, with 16.95% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 485.0% to 16.95% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 17.66% through Dec 2025, up 160.0% year-over-year, with the annual reading at 17.66% for FY2025, 160.0% up from the prior year.
  • EBITDA Margin hit 16.95% in Q4 2025 for Bausch Health Companies, down from 23.09% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 27.19% in Q3 2021 to a low of 12.86% in Q2 2021.
  • Historically, EBITDA Margin has averaged 10.5% across 5 years, with a median of 12.86% in 2024.
  • Biggest five-year swings in EBITDA Margin: crashed -2323bps in 2021 and later soared 2579bps in 2023.
  • Year by year, EBITDA Margin stood at 5.07% in 2021, then plummeted by -312bps to 10.76% in 2022, then soared by 240bps to 15.03% in 2023, then surged by 45bps to 21.81% in 2024, then decreased by -22bps to 16.95% in 2025.
  • Business Quant data shows EBITDA Margin for BHC at 16.95% in Q4 2025, 23.09% in Q3 2025, and 17.55% in Q2 2025.